1995
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell D, Davis P, Johnson C, Kuhlman J, Parisky Y, Runge V, Weinreb J, Bernardino M. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. American Journal Of Roentgenology 1995, 165: 1157-61. PMID: 7572495, DOI: 10.2214/ajr.165.5.7572495.Peer-Reviewed Original ResearchConceptsLesion-liver CNRLesion-liver contrastStandard doseHepatic lesionsMR imagingMalignant hepatic tumorsMalignant liver lesionsMalignant hepatic massesAdministration of gadoteridolMalignant hepatic lesionsT1-weighted spin-echo imagingLiver MR imagingStandard dosesHepatic massHepatic tumorsTriple doseHigh doseMalignant lesionsLiver lesionsLesionsLiver SNRDoseTime pointsGradient-echo imagingLiver signal
1994
Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging.
Mitchell D, Saini S, Weinreb J, De Lange E, Runge V, Kuhlman J, Parisky Y, Johnson C, Brown J, Schnall M. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994, 193: 49-57. PMID: 8090921, DOI: 10.1148/radiology.193.1.8090921.Peer-Reviewed Original Research